A live attenuated, cold-adapted influenzavirus vaccine was safe, immunogenic, and effective against influenza A(H3N2) and B in healthy children.

No abstract

Most outcomes related to influenza-like illness were significantly lower in intervention-school households than in control-school households. (ClinicalTrials.gov number, NCT00192218.)

The authors conducted a 2-year, multicenter, double-blind, placebo-controlled efficacy field trial of live, attenuated, cold-adapted, trivalent influenza vaccine administered by nasal spray to children 15-71 months old. Overall, vaccine was 92% efficacious at preventing culture-confirmed infection by influenza A/H3N2 and influenza B. Because influenza A/H1N1 did not cause disease during the years in which this study was conducted, the authors sought to determine vaccine efficacy and correlates of immune protection against experimental challenge with 107 TCID50 of attenuated H1N1 (vaccine strain) by intranasal spray. Prechallenge assessments included serum hemaglutination-inhibiting (HAI) antibody and nasal wash IgA antibody to H1N1. Vaccine was 83% efficacious (95% confidence interval, 60%-93%) at preventing shedding of H1N1 virus after challenge. Any serum HAI antibody or any nasal wash IgA antibody was correlated with significant protection from H1N1 infection as indicated by vaccine-virus shedding, and high efficacy against H1N1 challenge was demonstrated.

Pitcher. 2011. Cohort effects and spatial variation in age-specific survival of Steller sea lions from southeastern Alaska.Ecosphere 2(10):111. doi:10.1890/ES11-00215.1Abstract. Information concerning mechanistic processes underlying changes in vital rates and ultimately population growth rate is required to monitor impacts of environmental change on wildlife. We estimated age-specific survival and examined factors influencing survival for a threatened population of Steller sea lions (Eumetopias jubatus) in southeastern Alaska. We used mark-recapture models and data from 1,995 individuals marked at approximately one month of age at four of five rookeries in southeastern Alaska, and resighted from Oregon to the Bering Sea. Average annual survival probability for females was 0.64 for pups and 0.77 for yearlings, and increased from 0.91 to 0.96 from age 3-7 yrs. Annual survival probability of males averaged 0.60 for pups and 0.88 by 7 yrs, resulting in probability of survival to age 7, 33% lower for males compared to females. Pups from northern southeastern Alaska (including an area of low summer population size but rapid growth) were twice as likely to survive to age 7 compared to pups from southern rookeries (including a large, historical, stable rookery). Effects of early conditions on future fitness were observed as (1) environmental conditions in the birth year equally affected first-and secondyear survival, and (2) effects of body mass at approximately one month of age were still apparent at 7 yrs. Survival from 0-2 yrs varied among five cohorts by a maximum absolute difference of 0.12. We observed survival costs for long-distance dispersal for males, particularly as juveniles. However, survival was higher for non-pups that dispersed to northern southeastern Alaska, suggesting that moving to an area with greater productivity, greater safety, or lower population size may alleviate a poor start and provide a mechanism for spatial structure for sea lion populations.

No abstract

Lactoferrin supplementation was associated with potentially beneficial outcomes such as significantly fewer lower respiratory tract illnesses and higher hematocrits. Larger, more focused studies in infants are warranted.

Deletion of the NS2 gene attenuates RSV in subjects of all ages studied. This validates the strategy of developing live respiratory tract virus vaccines in which the virus's ability to inhibit the human innate immune system is blocked. rA2cp248/404 Delta NS2 should be studied in children at a higher input titer, because it was more infectious and immunogenic than was rA2cp530/1009 Delta NS2.